Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

Background: Programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitions are being strongly recommended for the treatment of various cancers, while the efficacy of PD-1/PD-L1 inhibitions varies from individuals. It is urgent to explore some biomarkers to screen the most appro...

Full description

Bibliographic Details
Main Authors:	Jiaxin Zhu, Tiantian Zhang, Jiahao Li, Junming Lin, Wenhua Liang, Wenjie Huang, Ning Wan, Jie Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Series:	Frontiers in Pharmacology
Subjects:	tumor mutation burden cancer PD-1/PD-L1 inhibitions biomarker meta-analysis
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.00673/full

Similar Items

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
by: Solène-Florence Kammerer-Jacquet, et al.
Published: (2019-04-01)

Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis
by: SHEN Shijun, et al.
Published: (2021-03-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
by: Ming Yi, et al.
Published: (2018-08-01)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
by: Weiting Qin, et al.
Published: (2019-10-01)

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
by: Cui Jiang, et al.
Published: (2019-09-01)

PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension
by: Lai Jiang, et al.
Published: (2018-05-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2019-04-01)

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2021-01-01)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020-08-01)

Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B
by: Wenjin Zhang, et al.
Published: (2012-08-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021-06-01)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
by: Youhai Jiang, et al.
Published: (2020-03-01)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
by: Ye Liu, et al.
Published: (2021-06-01)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
by: Feng Qi, et al.
Published: (2021-09-01)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
by: Florus C. de Jong, et al.
Published: (2021-03-01)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
by: Gang Xue, et al.
Published: (2019-08-01)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
by: Michael T. Barrett, et al.
Published: (2018-07-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
by: Yoon Ah Cho, et al.
Published: (2021-09-01)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
by: Fan Y, et al.
Published: (2016-10-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
by: Xianjie Jiang, et al.
Published: (2019-01-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer
by: Xiaoyu ZHI, et al.
Published: (2019-12-01)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
by: Wenxiao Jiang, et al.
Published: (2021-09-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
by: Stefanie Schatz, et al.
Published: (2020-06-01)

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells
by: Iosune Baraibar, et al.
Published: (2020-10-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)